Amarin (AMRN) Files Patent Suit Against AstraZeneca (AZN), Subsidiary

On March 4, 2014, Amarin Pharmaceuticals Ireland Limited, a wholly owned subsidiary of Amarin Corporation plc (Nasdaq: AMRN), filed a complaint in the United States District Court for the District of Delaware against Omthera Pharmaceuticals, Inc., a Delaware corporation, and its parent company, AstraZeneca Pharmaceuticals LP (NYSE: AZN). The suit seeks injunctive relief and monetary damages for infringement of Amarin’s U.S. Patent No. 8,663,662 (the “Patent”), which was issued by the United States Patent and Trademark Office today. The complaint alleges infringement of the Patent arising from the expected launch of EpanovaTM in the United States. The Patent covers methods of lowering triglycerides by administering a pharmaceutical composition that includes amounts of EPA as free acid, and no more than about 30% DHA. Amarin intends to pursue this litigation vigorously and aggressively protect its intellectual property rights. Patent litigation is a time-consuming and costly process. There can be no guarantee that Amarin will be successful in enforcing the Patent or that the Patent will not be successfully challenged and invalidated. Even if Amarin is successful in enforcing the Patent, the process could take years to reach conclusion.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Lumen Technologies (LUMN) to cut 7% staff
• Ciena (CIEN) Announces Retirement of Principal Accounting Officer Andrew C. Petrik
• Biodesix Inc. (BDSX) Files for 30.43M Share Offering by Selling Stockholders